Search

Author/Creator Gusenleitner, Daniel

1. 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. (9th November 2020)

Authors:
Lin, Chia-Chi; Garralda, Elena; Schöffski, Patrick; Hong, David; Siu, Lillian; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel; Cassier, Philippe; Sarantopoulos, John; Weickhardt, Andrew; Carvajal, Rich; Spratlin, Jennifer; ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A235
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Issue 3 (March 2020)

Authors:
Dummer, Reinhard; Brase, Jan C; Garrett, James; Campbell, Catarina D; Gasal, Eduard; Squires, Matthew; Gusenleitner, Daniel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Flaherty, Keith; Larkin, James; Robert, Caroline; Kefford, Richard; Kirkwood, John M; Hauschil...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 3(2020)
Page Start:
358
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. Issue 1 (6th March 2018)

Authors:
Subrahmanyam, Priyanka B.; Dong, Zhiwan; Gusenleitner, Daniel; Giobbie-Hurder, Anita; Severgnini, Mariano; Zhou, Jun; Manos, Michael; Eastman, Lauren M.; Maecker, Holden T.; Hodi, F. Stephen
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 6:Issue 1(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Issue 2 (25th February 2022)

Authors:
Schöffski, Patrick; Tan, Daniel S W; Martín, Miguel; Ochoa-de-Olza, María; Sarantopoulos, John; Carvajal, Richard D; Kyi, Chrisann; Esaki, Taito; Prawira, Amy; Akerley, Wallace; De Braud, Filippo; Hui, Rina; Zhang, Tian; Soo, Ross A; Maur, Michela; Weickhardt, Andrew; Krauss, Jürgen; Deschler-Bai...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 2(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Issue 6 (21st June 2022)

Authors:
Tawbi, Hussein A; Robert, Caroline; Brase, Jan C; Gusenleitner, Daniel; Gasal, Eduard; Garrett, James; Savchenko, Alexander; Görgün, Güllü; Flaherty, Keith T; Ribas, Antoni; Dummer, Reinhard; Schadendorf, Dirk; Long, Georgina V; Nathan, Paul D; Ascierto, Paolo A
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗